Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
3.250
-0.110 (-3.27%)
At close: May 27, 2026, 4:00 PM EDT
3.230
-0.020 (-0.62%)
After-hours: May 27, 2026, 7:41 PM EDT
Incannex Healthcare Revenue
In the fiscal year ending June 30, 2025, Incannex Healthcare had annual revenue of $86.00K with 616.67% growth.
Revenue (ttm)
$86.00K
Revenue Growth
+616.67%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
38.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 86.00K | 74.00K | 616.67% |
| Jun 30, 2024 | 12.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 1.42M | 1.01M | 240.90% |
| Jun 30, 2020 | 417.37K | - | - |
| Jun 30, 2019 | - | - | - |
| Jun 30, 2018 | 749.69K | 532.50K | 245.17% |
| Jun 30, 2017 | 217.19K | 148.89K | 217.98% |
| Jun 30, 2016 | 68.30K | - | - |
| Jun 30, 2015 | - | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | 32.66K | -35.13K | -51.82% |
| Jun 30, 2012 | 67.78K | 19.92K | 41.62% |
| Jun 30, 2011 | 47.86K | 25.69K | 115.86% |
| Jun 30, 2010 | 22.17K | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | 47.61K | 46.44K | 3,962.29% |
| Jun 30, 2006 | 1.17K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 84.76M |
| Rockwell Medical | 67.68M |
| Aytu BioPharma | 56.60M |
| BGM Group | 25.10M |
| SCYNEXIS | 20.34M |
| Zhengye Biotechnology Holding | 16.64M |
| China Pharma Holdings | 3.99M |
| TherapeuticsMD | 3.35M |
IXHL News
- 12 days ago - Incannex Healthcare Quarterly report: Q3 2026 - Filings
- 13 days ago - Incannex commences DReaMzz clinical study of IHL-42X in OSA - TheFly
- 13 days ago - Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea - GlobeNewsWire
- 15 days ago - Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development - GlobeNewsWire
- 20 days ago - Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough - GlobeNewsWire
- 5 weeks ago - Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness - GlobeNewsWire
- 5 weeks ago - Two new option listings on April 16th - TheFly
- 5 weeks ago - Two new option listings on April 16th - TheFly